UK Biobank, the world’s most significant source of data and biological samples for health research, is set to receive £127.6m to fund a move to a larger, faster, and more efficient, purpose-built facility at Bruntwood SciTech’s Manchester Science Park.
Ecosystem of industry mentors and corporate partners, including KPMG and Deloitte, to accelerate the potential of growing life sciences businesses
Bruntwood has reported one of the strongest set of figures in its 46-year history.
Bruntwood SciTech has announced the launch of Nest – its newest workspace offering for innovative, high-tech companies at Alderley Park.
Claritas Solutions has announced its move to Glasshouse at Bruntwood SciTech’s Alderley Park.
AIRSHIP Interactive has announced its plans to move its headquarters to South Manchester – bringing with it over 100 new jobs by mid-2023, and over 200 within the next three years.
Bruntwood SciTechhas submitted a planning application to deliver two new buildings for lab and office space at Alderley Park, Cheshire, totalling around 200,000 sq ft.
Bruntwood SciTech, the UK’s leading property provider dedicated to the growth of the science and technology sector, has launched 86,000 sq ft of redeveloped laboratories at Alderley Park, undertaken as part of its £247m masterplan.
Bruntwood SciTech’s 1 million sq ft masterplan for Manchester Science Park has taken another step forward as its £21m development, Base, reaches practical completion.
Bruntwood SciTech is inviting Manchester city centre residents, local businesses and other key stakeholders to attend a consultation for No.3 Circle Square.
Bruntwood SciTech has secured a deal with the Chi Yip Group to bring a new market hall and dining destination – Hello Oriental – to Circle Square, Manchester, in July 2021.
Bruntwood SciTech’s Alderley Park launches breakthrough oncology development programme in collaboration with cancer research UK, innovate UK, medicines discovery catapult and global pharma and healthcare companies
Some of the biggest names in UK cancer research and clinical excellence and four major global pharmaceutical and healthcare companies are combining forces to help accelerate the translation of emerging cancer research in the UK into patient benefits.